Lab
Mawd Pathology Group PA
Mawd Pathology Group PA was paid $5.96M by Medicaid between Jan 2018 and Dec 2024, across 37 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 21% of everything it billed.
33Billing provider infoMAWD PATHOLOGY GROUP PA
LENEXA, KS 66215
LENEXA, KS 66215
33aNPI1033108519assigned 10/18/2005
33bProvider typeClinical Medical Laboratory
28Total paid$5.96M
24GClaims215,291
24DCodes billed37
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Kansas
Rank by total paid#5 of 47
Median peer was paid$64K
This provider vs. median93×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,883 | $237K | |
| 2019 | 23,140 | $584K | |
| 2020 | 43,485 | $1.18M | |
| 2021 | 45,683 | $1.36M | |
| 2022 | 33,926 | $945K | |
| 2023 | 31,077 | $837K | |
| 2024incomplete | 27,097 | $821K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 21% | 36,549 | 22,309 | $1.25M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 15% | 17,485 | 16,041 | $922K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 14% | 31,237 | 28,846 | $823K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 14% | 31,165 | 28,753 | $820K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 8.2% | 25,247 | 23,264 | $486K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 7.7% | 18,045 | 16,982 | $462K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 4.1% | 11,256 | 9,839 | $247K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.8% | 16,154 | 10,023 | $227K |
| 88307 | 2.8% | 2,485 | 2,404 | $165K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.1% | 3,161 | 2,312 | $123K |
| 88142 | 1.8% | 8,039 | 7,155 | $109K | |
| 87481 | <1% | 1,981 | 1,375 | $49K |
25 more codes
| 88141 | <1% | 2,943 | $46K | |
| 88342 | <1% | 1,113 | $42K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,295 | $42K |
| 88312 | <1% | 1,458 | $32K | |
| 81513 | <1% | 321 | $29K | |
| 87511 | <1% | 922 | $19K | |
| 88304 | <1% | 1,457 | $18K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 384 | $17K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 972 | $16K |
| 87563 | <1% | 339 | $7K | |
| 88300 | <1% | 268 | $6K | |
| 88313 | <1% | 87 | $2K | |
| 81514 | <1% | 25 | $2K | |
| 87529 | <1% | 40 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 181 | $1K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 433 | $1K |
| 88302 | <1% | 122 | $936.34 | |
| 88341 | <1% | 21 | $858.62 | |
| 88112 | <1% | 27 | $684.47 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 13 | $224.56 |
| 86696 | <1% | 13 | $217.58 | |
| 86695 | <1% | 13 | $132.30 | |
| 85060 | <1% | 13 | $118.40 | |
| 87186 | <1% | 13 | $93.62 | |
| 87625 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILSON, JEFF (GENERAL MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Obstetrical Gynecological Associates of Des Moines PLC | Des Moines, IA | $825K |
| Mawd Pathology Partners PA | Lenexa, KS | $299K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.